Status:
UNKNOWN
Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Chronic Heart Failure: Cardiovascular Effects
Lead Sponsor:
University of Aarhus
Conditions:
Heart Failure
Ketosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The ketone body 3-hydroxybutyrate (3-OHB) is a naturally occurring energy substrate, and is associated with increased life span and improved health. We have previously shown that intravenous 3-OHB tre...
Detailed Description
Heart Failure (HF) is a major public health issue because the disease affects 1-2% of the Western population and the lifetime risk of HF is 20%. HF is responsible for 1-2% of all healthcare expenditur...
Eligibility Criteria
Inclusion
- Chronic Heart Failure;
- NYHA class II-III
- Left Ventricular Ejection Fraction \<40%
Exclusion
- Diabetes or HbA1c \> 48 mmol/mol
- Significant cardiac valve disease,
- Severe stable angina pectoris
- Severe comorbidity as judged by investigator,
- Inability to give informed consent.
Key Trial Info
Start Date :
April 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04443426
Start Date
April 25 2019
End Date
November 1 2022
Last Update
August 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8200